The trade policy actions announced in the early days of the Trump administration are set to have significant implications for the MedTech industry in APAC. Experts Alex Capri, author of Techno-Nationalism and Senior Lecturer at NUS Business School, and Neena Shenai, Partner at WilmerHale, examine the impact of new tariffs and trade barriers on APAC markets, the implications of regulatory shifts such as the pause in FCPA (Foreign Corrupt Practices Act) enforcement, and strategies for MedTech leaders to navigate these evolving challenges.